Perspective Therapeutics Inc CATX

$1.61 -0.65 (-28.76%)

Valuation

Market cap
257,984,000
Revenue TTM
$880,000
Net income TTM
$-103,120,000
PE ratio
0.00
Forward PE
—
Profit margin
-11,718.18%
Debt to equity
0.00

Trading

Volume
5,613,900
Avg volume
1,829,486
Day's range
$1.58 – $2.40
Shares out
114,152,000
Stochastic %K
3%
Beta
1.84
Analysts
Strong Sell
Price target
$12.29

Price

Company profile

Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previous...

Show more

Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. The company also develops Pluvicto, a betaemitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.

Industry
Medical Devices
Sector
Healthcare
Phone
206 676 0900
Website
https://www.perspectivetherapeutics.com
Address
2401 Elliott Avenue, Suite 320, Seattle, United States

Latest news

Stocktwits

Wences Oct 24, 4:08 PM
$CATX I sold it out completely and bought $NRXP instead. I Hope this will bring my loss back.
1 replies
RadioIsotope25 Oct 24, 1:29 AM
$CATX Data was less than before. Problem is that they have competition and this is crowded. I think they needed stronger data to seperate themselves that’s why it sold off. I am sure they want to partner this drug. So they can concentrate on less crowded indications.
2 replies
Eskayes Oct 23, 11:52 PM
$CATX feels like one pm dumped their position. Not massive volume today. Trades less than cash. Could be Nantahala. They’re big in AVTX which puked this week as well. Seems strange to dump a position worth maybe 4mm notional? I like it here for a trade. Biotech mafia is a strange group
0 replies
CM62 Oct 23, 11:43 PM
$CATX The entire market is in turmoil..with elections coming, Iran tensions, gas/oil ⬆️⬆️⬆️⬆️, who knows what will happen..
0 replies
CM62 Oct 23, 11:42 PM
$CATX I've been in this for years and years, then the split, now, who knows. The poster, Jack, gave such insightful info. He wasn't posted in awhile.. hope all good.
0 replies
watchaddict Oct 23, 11:07 PM
$CATX Had time to askb just added 4k more check back on monday Bloomberg AI likes it
0 replies
jto2 Oct 23, 11:00 PM
$CATX The CEO has repeatedly outlined the Phase 3 plan all year: - Hundreds of patients enrolled at US sites, not a traditional trial enrolling thousands - SSTR2-positive in all lesions - Physician’s choice comparator - PFS as the likely registration endpoint, with ORR potentially supporting an AA pathway - 20 mCi based on Cohort 2; Cohort 4 is testing front-loading, not redefining the dose My expectation is a Cohort 2-based AA pathway, followed by a Phase 3 confirmatory trial. Today, management reiterated the year-end target for Phase 3 site activation. Trial design, site selection, contracts, and other preparations need to be finalized well in advance. Given this timeline, an announcement clarifying the FDA registration trial design should be coming soon.
2 replies
elmono Oct 23, 10:59 PM
$CATX tried to avoid shitcos…I failed 😂😂😂……now I have to sell this crap for a 40% loss. Unfucking believable…..the good news: almost cured of investing in bio trash companies
0 replies